Totect: a new agent for treating anthracycline extravasation.
Anthracycline chemotherapy agents bind to DNA and cause cell death when they extravasate into healthy tissue. Although many approaches to managing extravasations have been studied and reported, data from two prospective clinical trials suggest that Totect (dexrazoxane for injection, TopoTarget USA, Inc.) is an effective anthracycline extravasation treatment. Only 1 of 54 patients with doxorubicin or epirubicin biopsy-confirmed extravasations treated with Totect developed tissue necrosis. Because nurses are on the forefront of extravasation prevention and management, they need to be knowledgeable about this new agent and how it is administered.
Schulmeister
Lisa
L
LisaSchulmeister@hotamil.com
D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000931:Antidotes / Q000627:therapeutic use; D001706:Biopsy; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003646:Debridement; D004334:Drug Administration Schedule; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D009336:Necrosis; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011929:Razoxane / Q000494:pharmacology / Q000627:therapeutic use*; D016038:Skin Transplantation; D013997:Time Factors
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000931:Antidotes; D002614:Chelating Agents; D011929:Razoxane